EpiBiome to Join Stanford’s StartX Accelerator

epibiomeEpiBiome, a South San Francisco, CA-based precision microbiome engineering company, has been accepted into Stanford’s StartX Accelerator Program.

Throughout the 16-week program, EpiBiome will receive mentorship from a community of more than 200 serial entrepreneurs, experts, angels and venture capitalists.
Additionally, Stanford will participate in the company’s B financing round, offering more than $400k in value from the program’s partners, all in exchange for zero equity.

Led by Dr. Nick Conley, co-founder and CEO, Aeron Tynes Hammack, PhD, Co-founder and COO, Christina Tsai, PhD, Co-founder & VP of Asian Business Development, Lucia Mokres, DVM, Chief Medical Officer, and Bruno Marchon, PhD, CTO, EpiBiome develops FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of small-molecule antibiotics. Its first product will address bovine mastitis, an inflammation of the udder tissue in dairy cows, usually caused by bacterial infection.
Backers in the company include Alexandria Venture Investments, China Rock Capital Management, Illumina Accelerator Boost Capital, Matrix Capital Management, SV Tech Ventures, and Viking Global Investors. It just received $1m in debt financing.



Join the discussion